AI Engines For more Details: Perplexity Kagi Labs You
Tendon Rupture: Like other fluoroquinolone antibiotics, clinafloxacin has been associated with an increased risk of tendon ruptures, particularly in the Achilles tendon. This risk may be higher in older adults, those taking corticosteroids, and individuals with a history of tendon disorders.
Peripheral Neuropathy: Clinafloxacin, along with other fluoroquinolones, has been linked to peripheral neuropathy, which involves damage to the nerves outside of the brain and spinal cord. Symptoms may include pain, tingling, numbness, or weakness in the extremities.
Central Nervous System Effects: Some individuals taking clinafloxacin may experience central nervous system side effects such as dizziness, headache, confusion, or hallucinations. These effects are usually reversible but can be concerning, especially in vulnerable populations.
Cardiovascular Effects: There have been reports of cardiovascular adverse effects associated with clinafloxacin, including QT interval prolongation, which can lead to a potentially life-threatening arrhythmia known as torsades de pointes.
Hepatotoxicity: Clinafloxacin can cause liver toxicity, leading to elevated liver enzymes, hepatitis, or liver failure in rare cases. Symptoms may include jaundice (yellowing of the skin or eyes), abdominal pain, or dark urine.
Photosensitivity: Like other fluoroquinolones, clinafloxacin may increase the skin's sensitivity to sunlight, leading to sunburn or skin rash with sun exposure.
Gastrointestinal Effects: Common gastrointestinal side effects of clinafloxacin may include nausea, vomiting, diarrhea, or abdominal discomfort.
Allergic Reactions: Some individuals may experience allergic reactions to clinafloxacin, which can manifest as rash, itching, swelling, or difficulty breathing. Severe allergic reactions like anaphylaxis are rare but can occur.
Musculoskeletal Effects: In addition to tendon ruptures, clinafloxacin may rarely cause muscle weakness or muscle pain, particularly in individuals with underlying muscle disorders.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Akkermansia muciniphila | Reduces |
| species | Bacteroides uniformis | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Escherichia coli | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
| species | Parabacteroides distasonis | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.9 | 0.9 | |
| Acne | 0.3 | -0.3 | |
| ADHD | 5.1 | 0.6 | 7.5 |
| Age-Related Macular Degeneration and Glaucoma | 1.1 | 0.4 | 1.75 |
| Allergic Rhinitis (Hay Fever) | 3.4 | 3 | 0.13 |
| Allergies | 7.1 | 3.4 | 1.09 |
| Allergy to milk products | 2.1 | 1.6 | 0.31 |
| Alopecia (Hair Loss) | 1.6 | 1.6 | |
| Alzheimer's disease | 6.6 | 8.3 | -0.26 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 3.4 | 1 | 2.4 |
| Ankylosing spondylitis | 4.9 | 1.8 | 1.72 |
| Anorexia Nervosa | 1.6 | 3.2 | -1 |
| Antiphospholipid syndrome (APS) | 2.1 | 0.3 | 6 |
| Asthma | 6.5 | 2.5 | 1.6 |
| Atherosclerosis | 2.7 | 2 | 0.35 |
| Atrial fibrillation | 4.1 | 3.1 | 0.32 |
| Autism | 11 | 11 | 0 |
| Autoimmune Disease | 1.2 | 1 | 0.2 |
| Barrett esophagus cancer | 0.6 | 0.3 | 1 |
| benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
| Biofilm | 3 | 3 | |
| Bipolar Disorder | 2.4 | 1.7 | 0.41 |
| Brain Trauma | 0.9 | 1.4 | -0.56 |
| Breast Cancer | 1.2 | 1.2 | |
| Cancer (General) | 0.9 | 3.4 | -2.78 |
| Carcinoma | 4.9 | 2.6 | 0.88 |
| Celiac Disease | 3.6 | 3.8 | -0.06 |
| Cerebral Palsy | 1.4 | 1.3 | 0.08 |
| Chronic Fatigue Syndrome | 6.6 | 7.7 | -0.17 |
| Chronic Kidney Disease | 5.2 | 3 | 0.73 |
| Chronic Lyme | 0.6 | 0.8 | -0.33 |
| Chronic Obstructive Pulmonary Disease (COPD) | 3 | 2 | 0.5 |
| Chronic Urticaria (Hives) | 2 | 1.3 | 0.54 |
| Coagulation / Micro clot triggering bacteria | 1.9 | 1.3 | 0.46 |
| Cognitive Function | 3.1 | 1.6 | 0.94 |
| Colorectal Cancer | 8.5 | 2.8 | 2.04 |
| Constipation | 2.1 | 0.7 | 2 |
| Coronary artery disease | 3 | 3 | 0 |
| COVID-19 | 11.6 | 14 | -0.21 |
| Crohn's Disease | 9.9 | 6 | 0.65 |
| Cushing's Syndrome (hypercortisolism) | 0.9 | -0.9 | |
| cystic fibrosis | 1.2 | 1.9 | -0.58 |
| d-lactic acidosis (one form of brain fog) | 0.6 | 0.6 | |
| deep vein thrombosis | 2.7 | 1.4 | 0.93 |
| Denture Wearers Oral Shifts | 2.1 | 2.1 | |
| Depression | 13.6 | 10.7 | 0.27 |
| Dermatomyositis | 0.3 | 0.3 | 0 |
| Eczema | 2.3 | 2.6 | -0.13 |
| Endometriosis | 3.5 | 2.6 | 0.35 |
| Eosinophilic Esophagitis | 0.3 | 0.6 | -1 |
| Epilepsy | 4 | 1.9 | 1.11 |
| erectile dysfunction | 1.4 | 0.3 | 3.67 |
| Fibromyalgia | 3.7 | 2.6 | 0.42 |
| Functional constipation / chronic idiopathic constipation | 6.9 | 4.9 | 0.41 |
| gallstone disease (gsd) | 4.3 | 1.2 | 2.58 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 2.4 | 1.2 | 1 |
| Generalized anxiety disorder | 3.4 | 2 | 0.7 |
| giant cell arteritis | 0.2 | -0.2 | |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 2.1 | 0.6 | 2.5 |
| Graves' disease | 1.9 | 3.3 | -0.74 |
| Gulf War Syndrome | 0.9 | 1.7 | -0.89 |
| Halitosis | 1.8 | 0.3 | 5 |
| Hashimoto's thyroiditis | 4 | 1.8 | 1.22 |
| Heart Failure | 5.4 | 1.9 | 1.84 |
| hemorrhagic stroke | 1.3 | 1.3 | |
| Hidradenitis Suppurativa | 1.4 | 0.3 | 3.67 |
| High Histamine/low DAO | 1.9 | 0.6 | 2.17 |
| hypercholesterolemia (High Cholesterol) | 1.1 | 0.1 | 10 |
| hyperglycemia | 3 | 1.3 | 1.31 |
| Hyperlipidemia (High Blood Fats) | 0.9 | 0.3 | 2 |
| hypersomnia | 0.7 | -0.7 | |
| hypertension (High Blood Pressure | 4.9 | 6.4 | -0.31 |
| Hypothyroidism | 0.1 | 1 | -9 |
| Hypoxia | 3.6 | 0.3 | 11 |
| IgA nephropathy (IgAN) | 1.9 | 5.5 | -1.89 |
| Inflammatory Bowel Disease | 10.5 | 11.2 | -0.07 |
| Insomnia | 2.5 | 2.6 | -0.04 |
| Intelligence | 2 | 0.6 | 2.33 |
| Intracranial aneurysms | 1.4 | 0.6 | 1.33 |
| Irritable Bowel Syndrome | 9.1 | 5.5 | 0.65 |
| ischemic stroke | 3.2 | 1.7 | 0.88 |
| Liver Cirrhosis | 8.7 | 5 | 0.74 |
| Long COVID | 8.3 | 8.8 | -0.06 |
| Low bone mineral density | 1.1 | -1.1 | |
| Lung Cancer | 1.5 | 1.1 | 0.36 |
| Lymphoma | 0.6 | 0.6 | |
| Mast Cell Issues / mastitis | 1.5 | 0.9 | 0.67 |
| ME/CFS with IBS | 1.1 | 2.4 | -1.18 |
| ME/CFS without IBS | 2 | 2.4 | -0.2 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 2.1 | 0.6 | 2.5 |
| Metabolic Syndrome | 9 | 8.6 | 0.05 |
| Mood Disorders | 13.1 | 8.6 | 0.52 |
| multiple chemical sensitivity [MCS] | 1.2 | 0.1 | 11 |
| Multiple Sclerosis | 8.1 | 7 | 0.16 |
| Multiple system atrophy (MSA) | 1.4 | 0.7 | 1 |
| myasthenia gravis | 0.9 | 0.7 | 0.29 |
| neuropathic pain | 0.3 | 3.2 | -9.67 |
| Neuropathy (all types) | 0.8 | 2.2 | -1.75 |
| neuropsychiatric disorders (PANDAS, PANS) | 1.2 | 1.2 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 6.5 | 5 | 0.3 |
| NonCeliac Gluten Sensitivity | 1.4 | 0.6 | 1.33 |
| Obesity | 11.9 | 9.7 | 0.23 |
| obsessive-compulsive disorder | 7 | 4.4 | 0.59 |
| Osteoarthritis | 3.3 | 1.2 | 1.75 |
| Osteoporosis | 2.5 | 1.4 | 0.79 |
| pancreatic cancer | 1.2 | 0.3 | 3 |
| Parkinson's Disease | 9.7 | 8.3 | 0.17 |
| Polycystic ovary syndrome | 7.9 | 3.3 | 1.39 |
| Postural orthostatic tachycardia syndrome | 0.2 | 0.6 | -2 |
| Premenstrual dysphoric disorder | 0.7 | 0.4 | 0.75 |
| primary biliary cholangitis | 1.2 | 1.7 | -0.42 |
| Primary sclerosing cholangitis | 3 | 3.2 | -0.07 |
| Psoriasis | 4 | 3.5 | 0.14 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 9.2 | 4.7 | 0.96 |
| Rosacea | 1.2 | 0.7 | 0.71 |
| Schizophrenia | 7.4 | 3.1 | 1.39 |
| scoliosis | 0.9 | 1.2 | -0.33 |
| Sjögren syndrome | 3.2 | 3.2 | 0 |
| Sleep Apnea | 2.2 | 1.8 | 0.22 |
| Slow gastric motility / Gastroparesis | 1.5 | 0.3 | 4 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 2.2 | 0.6 | 2.67 |
| Stress / posttraumatic stress disorder | 3.3 | 2.9 | 0.14 |
| Systemic Lupus Erythematosus | 4.9 | 2.4 | 1.04 |
| Tic Disorder | 1.5 | 1.8 | -0.2 |
| Tourette syndrome | 0.9 | 0.3 | 2 |
| Type 1 Diabetes | 4.6 | 4.4 | 0.05 |
| Type 2 Diabetes | 10 | 8.1 | 0.23 |
| Ulcerative colitis | 7 | 7.9 | -0.13 |
| Unhealthy Ageing | 6.8 | 2.5 | 1.72 |
| Vitiligo | 2.5 | 1.6 | 0.56 |
